Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Prevention of CINV in Cisplatin-Treated Patients
NCT03601871Phase 3Unknown
- Sponsor
- Yunpeng Liu
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of thalidomide in chemotherapy-induced nausea and vomiting (CINV), sponsored by Yunpeng Liu. Status: unknown.
02
Drugs
thalidomide
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03601871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601871.